mouse granzyme b elispot development module Search Results


mouse granzyme b elispot development module  (R&D Systems)
92
R&D Systems mouse granzyme b elispot development module
FIGURE 3. IL-12 enhances peptide sensitivity and decreases peptide specificity of OT-1 CTLs. A, Untreated and IL-12-treated OT-1 CTLs were tested for cytotoxicity against RMA-S cells pulsed with the intermediate agonist SIIGFEKL (106 M) (SD). Lysis of SIINFEKL at an E:T of 50:1 was 67% (no cytokine) and 78% (IL-12). Lysis with control peptide at an E:T ratio of 50:1 was 6% for both types of CTL. B, Untreated and IL-12-treated CTL were tested for cytotoxicity against RMA-S cells pulsed with the weak agonist/antagonist EIINFEKL (106 M; SD). Lysis of SIINFEKL at E:T 75:1 was 95% (No cytokine) and 100% (IL-12). Lysis with control peptide at E:T 75:1 was 5% for both types of CTL. C, Untreated and IL-12-treated OT-1 CTLs were tested for cytotoxicity against RMA-S cells pulsed with various concentrations of EIINFEKL at E:T 30:1 (SD). Lysis of SIINFEKL at 106 M was 65% (no cytokine) and 70% (IL-12). Lysis with control peptide at 106 M was 5% (no cytokine) and 15% (IL-12). D, The percentage (SD of three independent experiments) of untreated and IL-12-treated OT-1 CTLs that formed synapses with RMA-S cells pulsed with EIINFEKL (106 M). No cSMACs were formed. E, Percentage (SD) of untreated and IL-12-treated OT-1 CTLs that expressed IFN- as measured by intracellular staining. F, Percentage (SD) of untreated and IL-12-treated OT-1 CTLs that produced granzyme B as measured by an <t>ELISPOT</t> assay.
Mouse Granzyme B Elispot Development Module, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mouse+granzyme+b+elispot+development+module/pm19155481-91-1-10?v=R%26D+Systems
Average 92 stars, based on 1 article reviews
mouse granzyme b elispot development module - by Bioz Stars, 2026-07
92/100 stars
  Buy from Supplier

Image Search Results


FIGURE 3. IL-12 enhances peptide sensitivity and decreases peptide specificity of OT-1 CTLs. A, Untreated and IL-12-treated OT-1 CTLs were tested for cytotoxicity against RMA-S cells pulsed with the intermediate agonist SIIGFEKL (106 M) (SD). Lysis of SIINFEKL at an E:T of 50:1 was 67% (no cytokine) and 78% (IL-12). Lysis with control peptide at an E:T ratio of 50:1 was 6% for both types of CTL. B, Untreated and IL-12-treated CTL were tested for cytotoxicity against RMA-S cells pulsed with the weak agonist/antagonist EIINFEKL (106 M; SD). Lysis of SIINFEKL at E:T 75:1 was 95% (No cytokine) and 100% (IL-12). Lysis with control peptide at E:T 75:1 was 5% for both types of CTL. C, Untreated and IL-12-treated OT-1 CTLs were tested for cytotoxicity against RMA-S cells pulsed with various concentrations of EIINFEKL at E:T 30:1 (SD). Lysis of SIINFEKL at 106 M was 65% (no cytokine) and 70% (IL-12). Lysis with control peptide at 106 M was 5% (no cytokine) and 15% (IL-12). D, The percentage (SD of three independent experiments) of untreated and IL-12-treated OT-1 CTLs that formed synapses with RMA-S cells pulsed with EIINFEKL (106 M). No cSMACs were formed. E, Percentage (SD) of untreated and IL-12-treated OT-1 CTLs that expressed IFN- as measured by intracellular staining. F, Percentage (SD) of untreated and IL-12-treated OT-1 CTLs that produced granzyme B as measured by an ELISPOT assay.

Journal: Journal of immunology (Baltimore, Md. : 1950)

Article Title: IL-12 enhances CTL synapse formation and induces self-reactivity.

doi: 10.4049/jimmunol.182.3.1351

Figure Lengend Snippet: FIGURE 3. IL-12 enhances peptide sensitivity and decreases peptide specificity of OT-1 CTLs. A, Untreated and IL-12-treated OT-1 CTLs were tested for cytotoxicity against RMA-S cells pulsed with the intermediate agonist SIIGFEKL (106 M) (SD). Lysis of SIINFEKL at an E:T of 50:1 was 67% (no cytokine) and 78% (IL-12). Lysis with control peptide at an E:T ratio of 50:1 was 6% for both types of CTL. B, Untreated and IL-12-treated CTL were tested for cytotoxicity against RMA-S cells pulsed with the weak agonist/antagonist EIINFEKL (106 M; SD). Lysis of SIINFEKL at E:T 75:1 was 95% (No cytokine) and 100% (IL-12). Lysis with control peptide at E:T 75:1 was 5% for both types of CTL. C, Untreated and IL-12-treated OT-1 CTLs were tested for cytotoxicity against RMA-S cells pulsed with various concentrations of EIINFEKL at E:T 30:1 (SD). Lysis of SIINFEKL at 106 M was 65% (no cytokine) and 70% (IL-12). Lysis with control peptide at 106 M was 5% (no cytokine) and 15% (IL-12). D, The percentage (SD of three independent experiments) of untreated and IL-12-treated OT-1 CTLs that formed synapses with RMA-S cells pulsed with EIINFEKL (106 M). No cSMACs were formed. E, Percentage (SD) of untreated and IL-12-treated OT-1 CTLs that expressed IFN- as measured by intracellular staining. F, Percentage (SD) of untreated and IL-12-treated OT-1 CTLs that produced granzyme B as measured by an ELISPOT assay.

Article Snippet: The Mouse Granzyme B Elispot Development Module was purchased from R&D Systems, and the assay was performed following the manufacturer’s instructions.

Techniques: Lysis, Control, Staining, Produced, Enzyme-linked Immunospot